drugset / Trial / NCT03595865
Efficacy of Tafluprost as an Adjunct to Medical Therapy for Residual Glaucoma After Trabeculectomy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A 6-month, parallel-group study of the safety and efficacy of tafluprostin for Chinese patients with posttrabeculectomy residual primary angle-closure glaucoma or posttrabeculectomy residual primary open angle glaucoma.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2019-10-01
- Completion
- 2020-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tafluprostin | Unknown | 0.0015 % | — |